RudaCure, a company specializing in developing treatments for sensory disorders, announced that the lead compound development research for RCI002 — currently in development as a chronic pain treatment — has been selected as a supported project under the Korea Drug Development Fund (KDDF) National New Drug Development Program.
The National New Drug Development Program is a cross-ministerial R&D initiative that supports the full lifecycle of new drug development based on an open innovation strategy involving pharmaceutical companies, academia, research institutes, and hospitals, with the goal of strengthening the global competitiveness of Korea's pharmaceutical and biotech industries and securing pharmaceutical sovereignty as an essential national health requirement.
Through this program, RudaCure will receive approximately KRW 800 million in R&D funding over two years and will conduct joint research with the team of Professor Park Cheol-gyu at Gachon University College of Medicine, the lead institution.
The compound discovered by RudaCure selectively inhibits TRPV1 activity, and in prior research it demonstrated both TRPV1 inhibitory effects and pain reduction in chronic pain animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, making it expected to stand out as a highly effective analgesic with an excellent safety profile. Optimization research for commercialization will be carried out through this program.
RudaCure CEO Yongho Kim stated, "Through joint research with Professor Park Cheol-gyu's team at Gachon University College of Medicine, who has extensive research experience in pain, we can break away from the traditionally low-probability drug development approach and rapidly identify lead compounds using computational science methods, which significantly shortens drug development time — and this is very exciting."
RudaCure, 'TRPV1 Antagonist' Chronic Pain — "Selected for KDDF Project" (Biospectator)
http://www.biospectator.com/view/news_view.php?varAtcId=17129
Bio startup RudaCure selected for National New Drug Development Program for chronic pain treatment (Medical Today)
https://mdtoday.co.kr/news/view/1065586503001454
Non-narcotic chronic pain treatment selected for National New Drug Development Program (Medipharma)
http://www.medipharmnews.com/news/articleView.html?idxno=112361
Full-scale development of non-narcotic 'chronic pain treatment' begins (Herald Economy)
http://news.heraldcorp.com/view.php?ud=20220905000674
RudaCure "Non-narcotic 'chronic pain treatment' selected for National New Drug Development Program project" (Health Korea News)
https://www.hkn24.com/news/articleView.html?idxno=328843
RudaCure, non-narcotic 'chronic pain treatment' selected for National New Drug Development Program project (Medigate News)
http://www.medigatenews.com/news/3151924255
RudaCure, non-narcotic 'chronic pain treatment' selected for National New Drug Development Program project (Yakup Newspaper)
https://www.yakup.com/news/index.html?mode=view&cat=12&nid=273064
루다큐어 서울연구소